The company's portfolio selectively targets shared critical pathways that are the root cause of disease, and it is led by a team of global leaders in inflammation and autoimmunity. Viela Bio strives to be a fully integrated biotechnology company, helping millions of patients worldwide. Its lead molecule, inebilizumab, is a humanized monoclonal antibody designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company is located in Gaithersburg, Maryland, and was acquired by Horizon Therapeutics on March 15, 2021.